In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Trevena Inc (TRVN), with a price target of $1.25. The company’s shares closed yesterday at $1.43.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 9.3% and a 42.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Currently, the analyst consensus on Trevena Inc is a Moderate Buy with an average price target of $2.63.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.58 and a one-year low of $0.38. Currently, Trevena Inc has an average volume of 3.79M.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TRVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevena, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of healthcare services and development of therapies. The company product pipeline consists of Olinvo, TRV250, and TRV734.
Read More on TRVN:
